Search the Newsreel

AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) completed enrollment for the phase 2 study of ABCL-635 in treating …

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This …

Is AbCellera Biologics Inc (ABCL) Facing Headwinds After Q2 Earnings Miss? GF Score: 59/100

AbCellera Biologics Inc (ABCL) reported a significant Q2 2026 earnings miss with revenues of $4.1 million against an estimated $7.78 million and a net loss of $55.4 million. Despite the financial shortfall, the company maintains a strong liquidity position of over $565 million in …

Abcellera Biologics earnings missed, revenue fell short of estimates

Omnicell, Inc. (NASDAQ: OMCL) returns to profit with Q2 2026 growth

OMNICELL, INC. 2026: Revenue $312.21M, EPS $0.52— 10-Q Summary

Omnicell, Inc. (OMCL) reported strong financial results for the quarter ended 2026, with revenue reaching $312.21M and diluted EPS of $0.52. This growth was driven by increased product and service sales, improved margins, and strategic shifts towards platform offerings and recurring revenue. The company …

Celldex Therapeutics earnings up next as Phase III data looms By Investing.com

Celldex Therapeutics is set to report its second-quarter earnings, with investors focusing on the timing of topline data from its pivotal Phase III EMBARQ-CSU studies, expected in September to October. Analysts project a loss of $1.06 per share on revenue of $803,000, and Wall …

Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com

Celldex Therapeutics stock reached a 52-week high of $40.30, showcasing significant investor confidence with an 86.85% increase over the past year. Despite this surge and a market capitalization of $3.16 billion, InvestingPro data suggests the stock is currently overvalued. The company faces mixed news, …

Millicom faces earnings test after Q1 miss, expansion push

Millicom International Cellular SA is set to report second-quarter earnings, with analysts expecting improvements after a disappointing Q1. The company's recent strategic moves, including the acquisition of Telefónica’s stake in Coltel and infrastructure investments in Central America, will be under scrutiny to determine if …

AbCellera earnings on deck: Revenue dips as biotech eyes menopause trial

AbCellera Biologics Inc. is preparing to report its second-quarter results, with analysts forecasting a revenue decline despite recent partnership announcements. The company's cash management and the upcoming Phase 2 data readout for its lead menopause drug candidate, ABCL635, are key investor watch points. This …

Cellebrite DI Ltd. (CLBT) stock price, news, quote and history

This page provides a comprehensive overview of Cellebrite DI Ltd. (CLBT) stock, including its current price, historical data, news, and financial information. Cellebrite specializes in developing software and services for legally sanctioned investigations, covering digital evidence collection and analysis across various crime types. The …

AbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Castrol, Cello World, New India Assurance, Deepak Nitrite shares surge amid spike in volumes

Doosan Fuel Cell Exports 'Fuel Cell Heart' SOFC Stack to Europe in approximately $76.3 Million Deal

Doosan Fuel Cell Co., Ltd Secures First Export of Core Solid Oxide Fuel Cell Components

Citadel entities (NASDAQ: FCEL) disclose 3.8% FuelCell Energy position

Citadel-affiliated entities and Kenneth Griffin have disclosed a collective beneficial ownership of 3,015,372 shares, or 3.8% of FuelCell Energy (NASDAQ: FCEL), through a SCHEDULE 13G SEC filing. Citadel Securities LLC alone holds 2.7% of the shares. All reported parties hold shared voting and dispositive …

FuelCell Energy Inc. stock rises Tuesday, outperforms market

Shares of FuelCell Energy Inc. (FCEL) rose 5.44% to $22.50 on Tuesday, outperforming the broader market. The NASDAQ Composite Index increased by 2.59% and the Dow Jones Industrial Average rose by 1.71%. This gain ended a two-day losing streak for FuelCell Energy Inc.

Empery Asset Management (CLRB) discloses 9.99% beneficial stake via stock and warrants

Empery Asset Management, LP and Ryan M. Lane have reported a beneficial ownership of 9.99% in Cellectar Biosciences, Inc. (CLRB) through a Schedule 13G filing. This stake includes 864,090 shares, with 674,485 shares issuable upon the exercise of warrants, all subject to a 9.99% …

OMCL|Omnicell Inc|Price:37.525|Chg%:+2.155

This article provides a comprehensive stock analysis of Omnicell Inc (OMCL), highlighting its relatively healthy fundamentals, significant growth potential, and fair valuation. Despite recent weak stock market performance, the company maintains strong fundamentals, and analysts have issued "Buy" ratings with a high price target. …

Arrowstreet Capital Limited Partnership Trims Stock Position in Turkcell Iletisim Hizmetleri AS $TKC

Arrowstreet Capital Limited Partnership significantly reduced its stake in Turkcell Iletisim Hizmetleri AS (NYSE:TKC) by 49.5% in the first quarter, selling over 750,000 shares but still retaining a holding worth approximately $4.66 million. While Arrowstreet decreased its position, other institutional investors like JPMorgan Chase …

Why Did BriaCell Therapeutics Corp. (TSX:BCT) Stock Fall 5.49% on 31 July 2026?

Cello World Q1 Results: Earnings call scheduled for Aug 10

Weekly Recap: Omnicell, Inc. Q3/2026 revenue and analyst price target

Omnicell, Inc. (OMCL) reported Q3 revenue between $301-$307 million and guided 2026 revenue to $1.225-$1.245 billion, with an estimated year-end ARR of $660-$680 million. Analysts are optimistic, with a median 12-month price target of $60, suggesting a 31% upside, and the company recently appointed …

RGC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regencell Bioscience Holdings Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) and its officers. The lawsuit alleges that Regencell made materially false and misleading statements regarding its business, operations, and compliance policies between October 28, 2024, and October …

Omnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability

Omnicell (OMCL) reported stronger Q2 2026 revenue and net income, alongside improved profitability for the first half of 2026. The company also raised its full-year 2026 revenue guidance to between US$1.23 billion and US$1.25 billion, signaling higher expectations. Despite the positive outlook, the stock …

Omnicell (OMCL) Stock May Be 42% Below Fair Value On Weak Guidance

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Omnicell stock is currently caught between two different valuation signals. The Discounted Cash Flow (DCF) estimate points to meaningful upside to intrinsic value, …

Abcellera Biologics Inc expected to post a loss of 14 cents a share - Earnings Preview

Abcellera Biologics Inc (ABCL) is projected to report a loss of 14 cents per share. This earnings preview is based on Refinitiv data and was published by Reuters.

FLNC Stock Plummets 52% in 6 Months: Should You Buy in the Dip?

Shares of Fluence Energy FLNC have declined 52% over the past six months, underperforming the Zacks Alternate Energy - Other industry, as well as fellow industry players FuelCell Energy FCEL and GE Vernova GEV. 6- Month Stock Price ComparisonZacks Investment Research Image Source: Zacks …

Siemens and FuelCell Energy Collaborate to Accelerate On-Site Power Deployment

Siemens Smart Infrastructure and FuelCell Energy are partnering to expedite the deployment of large-scale, on-site fuel cell-based power generation projects, especially for data centers. Siemens will provide electrical balance of plant (EBOP) systems to FuelCell Energy, aiming to improve timelines, reduce costs, and increase …

Lazard Asset Management LLC Makes New Investment in Cellebrite DI Ltd. $CLBT

Lazard Asset Management LLC has acquired 154,863 shares of Cellebrite DI Ltd. (NASDAQ:CLBT) worth approximately $2.13 million, representing a 0.06% stake in the company. Institutional investors and hedge funds own 45.88% of Cellebrite DI, while recent insider activity shows sales by the CEO and …

FuelCell Energy (FCEL) Pulled Back After An AI Power Rally, Is The Stock Expensive?

FuelCell Energy (FCEL) experienced a profit-taking pullback after an AI power rally, with its share price falling 8.51% in the last day and 32.24% over 30 days, yet still showing significant 90-day and year-to-date returns. While analysts peg its fair value at $22 based …

CLLS|Cellectis SA|Price:2.920|Chg%:+0.170

This article provides a comprehensive stock analysis of Cellectis SA (CLLS) by TradingKey, detailing its financial health, valuation, growth potential, and institutional confidence. The company is described as a France-based genome engineering firm with significant revenue growth and a "Buy" analyst rating despite a …

Renaissance Technologies LLC Purchases 369,107 Shares of Turkcell Iletisim Hizmetleri AS $TKC

Renaissance Technologies LLC increased its stake in Turkcell Iletisim Hizmetleri AS (NYSE:TKC) by 28.8% in the first quarter, acquiring an additional 369,107 shares, bringing its total holdings to 1.65 million shares valued at $9.95 million. Other institutional investors also adjusted their positions, and analysts …

Omnicell Promotes Chief Operating Officer Nnamdi Njoku to President

Omnicell has promoted its Chief Operating Officer, Nnamdi Njoku, to President, expanding his role to include directing long-term growth, product development, and overseeing global operations. Njoku, who joined Omnicell less than two years ago, will also lead the launch of the Titan XT system …

Millicom International Cellular SA $TIGO Stock Position Increased by Amundi

Amundi significantly increased its stake in Millicom International Cellular SA (TIGO) by 120.8% in the first quarter, now holding over 529,000 shares valued at $39.7 million. This comes as Millicom reported strong quarterly earnings, beating EPS estimates, though analyst sentiment remains mixed with a …

CelLBxHealth study detects drug targets on cancer cells rivals would miss - UPDATE